



COVID-19 Variant Surveillance Report

Week ending July 31, 2021 (MMWR week 30)


Variant Surveillance- Cumulative Summary

Lineage (WHO Classification)	Proportion of Variant Sequenced	Proportion of Variant				
	from Dec 20, 2020 (%)	Sequenced in last 4 weeks (%)				
Variant of Concern						
B.1.1.7 (Alpha)	34.8%	1.6%				
B.1.617.2, AY.1, AY.2, AY.3 (Delta) [§]	13.8%	93.5%				
P.1 (Gamma)	2.2%	1.1%				
B.1.351 (Beta)	0.1%	0.0%				
Variant of Interest						
B.1.526 (lota)	21.6%	0.4%				
B.1.526.1	3.0%	0.0%				
B.1.427, B.1.429 (Epsilon)*	1.2%	0.0%				
B.1.525 (Eta)	0.2%	0.0%				
P.2 (Zeta)	0.1%	0.0%				
B.1.617	0.1%	0.0%				
B.1.617.1 (Kappa)	0.1%	0.0%				
Other Lineages	23.0%	3.4%				
Total Number of Specimens Sequenced**	16151	1842				

[§] Delta includes AY. 1, AY.2 and AY.3 variants. SARS-CoV-2 variants AY.1, AY.2 and AY.3 are no longer aggregated with B.1.617.2.

For CDC definitions of variant of concern and variant of interest visit: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern

COVID-19 Variant Surveillance by Specimen Collected Week- Cumulative Summary




Percentages represent the proportion found in the specified variant lineage. "Other" represents 158 additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

^{*} Deescalated from a Variant of Concern on June 29, 2021, due to the significant decrease in the proportion of B.1.429 lineage viruses circulating nationally and available data.

^{**} Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

^{*}Specimens collected 7/18/2021 – 7/31/2021 reflects data for two weeks with a total of 1282 specimens.

COVID-19 Variant Surveillance by State Region- Previous 4 weeks Summary*



Variant Details

WHO Label	Name (Pango Lineage)	First Detected	CDC Variant Classification	WHO Label
Alpha	B.1.1.7	United Kingdom	Variant of Concern	Alpha
Beta	B.1.351	South Africa	Variant of Concern	Beta
Delta	B.1.617.2, AY.1, AY.2, AY.3	India	Variant of Concern	Delta
Gamma	P.1	Brazil	Variant of Concern	Gamma
Epsilon	B.1.427, B.1.429	USA-California	Variant of Interest	Epsilon
Eta	B.1.525	USA-New York	Variant of Interest	Eta
lota	B.1.526	USA-New York	Variant of Interest	lota
	B.1.526.1	USA-New York	Variant of Interest	
Zeta	P.2	Brazil	Variant of Interest	Zeta
	B.1.617	India	Variant of Interest	
Карра	B.1.617.1	India	Variant of Interest	Карра

*Each regional chart represents the proportion of the specified variant lineage and is based on sequencing results from the 4 weeks prior to the week of July 31, 2021. There is an approximately 14-24-day time lag between specimen collection and report of sequencing results to NJDOH. "Other" represents additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

Data reported is based on a subset of sampled specimens from NJ residents sequenced for COVID-19 variant surveillance.